Harpoon_logo (002).jpg
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTACâ„¢ Platform
June 04, 2021 16:00 ET | Harpoon Therapeutics
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:04 ET | Harpoon Therapeutics
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...
Harpoon_logo (002).jpg
Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors
March 24, 2021 17:09 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021
March 11, 2021 13:16 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 10, 2021 16:05 ET | Harpoon Therapeutics
Provided positive update on its four TriTAC® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer Nominated first...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in 33rd Annual Roth Conference
March 09, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update
March 04, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
February 17, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma
January 13, 2021 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon_logo (002).jpg
Harpoon Therapeutics Announces Closing of Public Offering of Common Stock
January 11, 2021 16:01 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its...